Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

Thalassemia and sickle cell anaemia are common genetic disorders in India. Early testing, prenatal screening, and improved ...

I thought you could help with a stubborn problem. I am a healthy and active 78-year-old woman who, I admit, likes to look ...

The following is a summary of “Assessment of ferritin and hepcidin levels in splenectomised and non-splenectomised ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

The government has planned to launch a nationwide awareness campaign on prevention of Thalassemia in the country. Managing Director, Pakistan Bait-ul-Mal, Amir Fida Paracha in an interview said that ...

Hedge funds are rapidly reducing their exposure to global information technology stocks, with the latest sell-off marking the fastest decline in six months. Most sales are reported to be in ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

In addition to the cell therapy programmes, for example, it is also working with CRISPR Therapeutics on CTX001, a gene-editing therapy for beta thalassemia and sickle cell disease. “We have ...

Peter Gratton, M.A.P.P., Ph.D., is a New Orleans-based editor and professor with over 20 years of experience in investing, risk management, and public policy. Peter began covering markets at ...